Literature DB >> 14555992

Multigene methylation analysis of Wilms' tumour and adult renal cell carcinoma.

Mark R Morris1, Luke B Hesson, Kate J Wagner, Neil V Morgan, Dewi Astuti, Robert D Lees, Wendy N Cooper, JouAnn Lee, Dean Gentle, Fiona Macdonald, Takeshi Kishida, Richard Grundy, Masahiro Yao, Farida Latif, Eamonn R Maher.   

Abstract

To investigate the role of epigenetic gene silencing in the pathogenesis of Wilms' tumour and renal cell carcinoma (RCC), we determined their methylation profile using a candidate gene approach. Thus, 40 Wilms' tumours and up to 49 adult RCC were analysed by methylation-specific PCR for promoter methylation at CASP8, CDH1, CDH13, DAPK, MGMT, NORE1A, p14ARF and RARB2 in primary Wilms' tumours and CASP8, CDH1, CDH13, CRBP1, DAPK, MGMT, MT1G, NORE1A, p16INK4a, SDHB and RARB2 in primary RCC. Both tumour sample sets had previously been analysed for RASSF1A promoter methylation, and p16INK4a methylation results were also available for the Wilms' tumour samples. Wilms' tumours demonstrated a high incidence of methylation at CASP8 (43%) and MGMT (30%), intermediate frequencies at NORE1A (15%), p14ARF (15%), p16INK4a (10%), DAPK (11%) and CRBP1 (9%), but promoter methylation was rare or absent at RARB2 (0%), CDH13 (0%) and CDH1 (3%). No association was detected between methylation of RASSF1A, CASP8 or MGMT in individual tumours. The frequency of MGMT methylation was higher in stage 1 and 2 tumours (50%) than in stage 3 and 4 tumours (17%) but this did not reach statistical significance (P=0.06). RCC were most frequently methylated at DAPK (24%), MT1G (20%), NORE1A (19%), CDH1 (16%) and MGMT (9%) and not or rarely at SDHB (4%), RARB2 (0%), p16INK4a (0%) and CDH13 (3%). There were no associations between methylation of RASSF1A, DAPK and CDH1 in individual tumours. Papillary RCC demonstrated a higher frequency of DAPK methylation (43%) than clear cell tumours (19%) (P=0.14). We have demonstrated that de novo promoter methylation is frequent in Wilms' tumour and RCC, and these data enable methylation profiles to be constructed for each tumour type. Thus, combining our results with data published previously, it appears that promoter methylation occurs frequently (> or =20% of primary tumours) at CASP8, SLIT2 and RASSF1A in Wilms' tumour and at RASSF1A, TIMP3, DAPK, SLIT2, MT1G and GSTP1 in RCC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14555992     DOI: 10.1038/sj.onc.1206914

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

Review 1.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

2.  Characterization of a 3;6 translocation associated with renal cell carcinoma.

Authors:  Rebecca E Foster; Mahera Abdulrahman; Mark R Morris; Elena Prigmore; Susan Gribble; Beeling Ng; Dean Gentle; Steven Ready; Phil M T Weston; Michael S Wiesener; Takeshi Kishida; Masahiro Yao; Val Davison; Jose Luis Barbero; Carol Chu; Nigel P Carter; Farida Latif; Eamonn R Maher
Journal:  Genes Chromosomes Cancer       Date:  2007-04       Impact factor: 5.006

3.  DNA Methylation and Flavonoids in Genitourinary Cancers.

Authors:  Neelam Mukherjee; Addanki P Kumar; Rita Ghosh
Journal:  Curr Pharmacol Rep       Date:  2015-04-01

Review 4.  The epigenetic landscape of renal cancer.

Authors:  Mark R Morris; Farida Latif
Journal:  Nat Rev Nephrol       Date:  2016-11-28       Impact factor: 28.314

5.  Tumor suppressor ras association domain family 5 (RASSF5/NORE1) mediates death receptor ligand-induced apoptosis.

Authors:  Jikyoung Park; Soo Im Kang; Sun-Young Lee; Xian F Zhang; Myoung Shin Kim; Lisa F Beers; Dae-Sik Lim; Joseph Avruch; Ho-Shik Kim; Sean Bong Lee
Journal:  J Biol Chem       Date:  2010-09-01       Impact factor: 5.157

6.  Expression and roles of Slit/Robo in human ovarian cancer.

Authors:  Cai Feng Dai; Yi Zhou Jiang; Yan Li; Kai Wang; Pei Shu Liu; Manish S Patankar; Jing Zheng
Journal:  Histochem Cell Biol       Date:  2011-04-05       Impact factor: 4.304

7.  Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.

Authors:  Donghao Shang; Tiandong Han; Xiuhong Xu; Yuting Liu
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

8.  Genome-wide screen of promoter methylation identifies novel markers in melanoma.

Authors:  Yasuo Koga; Mattia Pelizzola; Elaine Cheng; Michael Krauthammer; Mario Sznol; Stephan Ariyan; Deepak Narayan; Annette M Molinaro; Ruth Halaban; Sherman M Weissman
Journal:  Genome Res       Date:  2009-06-02       Impact factor: 9.043

9.  Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors.

Authors:  Laxmi Chilukamarri; Anne L Hancock; Sally Malik; Joanna Zabkiewicz; Jenny A Baker; Alexander Greenhough; Anthony R Dallosso; Tim Hui-Ming Huang; Brigitte Royer-Pokora; Keith W Brown; Karim Malik
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

10.  Frequent long-range epigenetic silencing of protocadherin gene clusters on chromosome 5q31 in Wilms' tumor.

Authors:  Anthony R Dallosso; Anne L Hancock; Marianna Szemes; Kim Moorwood; Laxmi Chilukamarri; Hsin-Hao Tsai; Abby Sarkar; Jonathan Barasch; Raisa Vuononvirta; Chris Jones; Kathy Pritchard-Jones; Brigitte Royer-Pokora; Sean Bong Lee; Ceris Owen; Sally Malik; Yi Feng; Marcus Frank; Andrew Ward; Keith W Brown; Karim Malik
Journal:  PLoS Genet       Date:  2009-11-26       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.